Minerva Neurosciences, Inc. (NERV)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Dr. Remy Luthringer Ph.D.
|
Executive Chairman, CEO & Member of Scientific Advisory Board | 1.16M | -- | 1961 |
|
Mr. Frederick W. Ahlholm CPA
|
Senior VP, CFO & Secretary | 649.21k | -- | 1966 |
|
Mr. Joseph Reilly
|
Senior VP & COO | 461k | -- | 1975 |
|
Mr. Anthony Aliquo
|
Chief Accounting Officer & Principal Accounting Officer | -- | -- | 1987 |
|
Mr. William B. Boni
|
Vice President of Investor Relations & Corporate Communications | -- | -- | 1952 |
|
Mr. James O'Connor
|
Chief Business Officer & General Counsel | -- | -- | 1974 |
|
Prof. Michael Davidson M.D.
|
Member of Scientific Advisory Board & Chief Medical Officer | 657.47k | -- | 1950 |
Minerva Neurosciences, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 7
Description
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
Corporate Governance
Upcoming Events
Upcoming Events Information Not Available
Recent Events
March 17, 2026 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
